An FDA AdCom in September recommended against full approval for Ocaliva by a 13-...
A Phase IIb/III trial with infants entering their first respiratory syncytial vi...
The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which h...
An 800% increase in licensing deal values indicates growing confidence in mRNA t...
Radiopharm Theranostics (RAD) and AtomVie have announced a partnership for the d...
Strategic restructuring will support the ongoing launch of the oral postpartum d...
Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety ...
Fresenius Kabi and Cellular Origins have announced a partnership to advance cell...
The company’s keratoconus medication, Epioxa, was effective in a Phase III trial...
Acadia Pharmaceuticals has received marketing authorisation from Health Canada f...
Lexicon Pharmaceuticals has entered a licensing agreement with Viatris to commer...
J&J has cut two Phase II programmes and one Phase I asset in its neuroscience po...
Lilly’s senior VP of information and R&D IT Ramesh Durvasula said Lilly will use...
bit.bio’s method for pluripotent stem cell (PSC) programming, opti-ox, was deeme...
Almirall has completed the decentralised regulatory procedure in Europe for efin...
Discover the leading Parenteral Solutions in Pharmaceutical Contract Manufacturi...
